Johnson & Johnson Investor Presentation — January 2018

Document content

224thQuarter and Full Year 2017

Earnings Call Presentation

January 23, 201 833Joseph J. Wolk

Strong 4thQuarter & Full Year Results

Adjusted Earnings Growth

2ndHalf Sales Acceleration

Strength in Pharma & improving Medical Devices

Significant Acquisitions,

Collaboration Agreements

5Cautionary Note on Forward -Looking Statements

This presentation contains “forward -looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regar ding, among other things, future operating

and financial performance, product development, market position and business strategy. The viewer is cautioned not to rely on these forward -looking statements. These

statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual

results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, bu t are not limited to: economic and financial

market factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by

competitors; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of

commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic

plans, including restructuring plans; the impact of business combinations and divestitures; significant adverse litigation or government action, including related to product